Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders

• US 6,770,620 B2
• Filed: 09/17/2001
• Issued: 08/03/2004
• Est. Priority Date: 09/18/2000
• Status: Expired due to Fees

• Current Assignee: Sanos Bioscience A/S (C.C. Consulting A/S)
• Original Assignee: Sanos Bioscience A/S (C.C. Consulting A/S)
• Inventors: Henriksen, Dennis Bang
• Primary Examiner(s): Brumback, Brenda
• Assistant Examiner(s): Gupta, Anish
• Application Number:
  US09/954,304
• Publication Number:
  US 20020037836A1
• Time in Patent Office: 1,051 Days
• Field of Search: 514/2, 514/12, 514/102, 514/108, 530/308, 530/324, 530/303, 530/300
• US Class Current: 514/11.7
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/18 : of the parathyroid hormones
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 : Antihypertensives

Abstract

The present invention relates to methods for prevention and treatment of bone-related or nutrition-related disorders using a GLP molecule or GLP activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

Claims

1. A pharmaceutical composition comprising an effective amount of:

(a) a GLP-2; and

(b) another therapeutic agent which is an anti-osteoporosis agent.

3. The pharmaceutical composition of any one of claim 1 or 2, wherein the composition further comprises a pharmaceutically acceptable carrier.

2. A pharmaceutical composition comprising an effective amount of:

(a) a GLP-2; and

(b) another therapeutic agent which is an anti-osteoporosis agent, wherein the anti-osteoporosis agent is alendronate sodium, clodronate, etidronate, gallium nitrate, mithramycin, norethindrone acetate, pamidronate, or risedronate sodium.